Sfoglia per Autore
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center.
2019 Barbolini, M; Omarini, C; Viola, L; Isca, C; Marchi, I; Caggia, F; Barbieri, E; Toss, A; Cortesi, L; Dominici, M; Piacentini, F.
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC).
2019 Omarini, Claudia; Piacentini, Federico; Frassoldati, Antonio; Musolino, Antonino; Dominici, Massimo; Moscetti on behalf of GOIRC, Luca
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
2019 Omarini, C; Palumbo, P; Pecchi, A; Draisci, S; Balduzzi, S; Nasso, C; Barbolini, M; Isca, C; Bocconi, A; Moscetti, L; Galetti, S; Tazzioli, G; Torricelli, P; Cascinu, S; Piacentini, F.
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials.
2019 Omarini, Claudia; Piacentini, Federico; Sperduti, Isabella; Barbolini, Monica; Isca, Chrystel; Nasso, Cecilia; Toss, Angela; D'Onofrio, Raffaella; Cortesi, Laura; Barbieri, Elena; Cascinu, Stefano; Moscetti, Luca
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
2019 Pignata, S.; Scambia, G.; Lorusso, D.; De Giorgi, U.; Nicoletto, M. O.; Lauria, R.; Mosconi, A. M.; Sacco, C.; Omarini, C.; Tagliaferri, P.; Ferrandina, G.; Cinieri, S.; Savarese, A.; Valabrega, G.; Pisano, C.; Salutari, V.; Raspagliesi, F.; Kopf, B.; Cecere, S. C.; Amadio, G.; Maltese, G.; Di Napoli, M.; Greggi, S.; Signoriello, S.; Daniele, G.; Sacco, A.; Losito, S.; Normanno, N.; Perrone, F.; Gallo, C.; Piccirillo, M. C.
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series.
2020 Barbolini, Monica; Omarini, Claudia; Toss, Angela; Cortesi, Giulia; Fiorani, Claudia; Piombino, Claudia; Dominici, Massimo; Piacentini, Federico
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer
2020 Isca, Chrystel; Omarini, Claudia; Cortesi, Giulia; Moscetti, Luca; Barbolini, Monica; Dominici, Massimo; Piacentini, Federico
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
2020 Omarini, C.; Piacentini, F.; Sperduti, I.; Barbolini, M.; Isca, C.; Toss, A.; Cortesi, L.; Barbieri, E.; Dominici, M.; Moscetti, L.
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis
2020 D'Onofrio, R.; Omarini, C.; Barbolini, M.; Nasso, C.; Isca, C.; Dominici, M.; Piacentini, F.
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery.
2020 Nasso, C.; Barbolini, M.; Isca, C.; D'Onofrio, R.; Cortesi, G.; Dominici, M.; Piacentini, F.; Omarini, C.
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis.
2020 Barbolini, M.; Omarini, C.; Bettelli, S.; Manfredini, S.; Dominici, M.; Piacentini, F.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting
2020 Pizzuti, L; Krasniqi, E; Barchiesi, G; Della Giulia, M; Izzo, F; Sanguineti, G; Marchetti, P; Mazzotta, M; Giusti, R; Botticelli, A; Gamucci, T; Natoli, C; Grassadonia, A; Tinari, N; Iezzi, L; Tomao, S; Tomao, F; Tonini, G; Santini, D; Astone, A; Michelotti, A; De Angelis, C; Mentuccia, L; Vaccaro, A; Magnolfi, E; Gelibter, A; Magri, V; Cortesi, E; D'Onofrio, L; Cassano, A; Rossi, E; Cazzaniga, M; Moscetti, L; Omarini, C; Piacentini, F; Fabbri, Ma; Scinto, Af; Corsi, D; Carbognin, L; Bria, E; La Verde, N; Samaritani, R; Garufi, C; Barni, S; Mirabelli, R; Sarmiento, R; Veltri, E; D'Auria, G; Paris, I; Giotta, F; Lorusso, V; Cardillo, F; Landucci, E; Mauri, M; Ficorella, C; Roselli, M; Adamo, V; Ricciardi, Grr; Russo, A; Berardi, R; Pistelli, M; Fiorio, E; Cannita, K; Sini, V; D'Ostilio, N; Foglietta, J; Greco, F; Zamagni, C; Garrone, O; Di Cocco, B; Baldini, E; Livi, L; Desideri, I; Meattini, I; Sarobba, G; Del Medico, P; De Tursi, M; Generali, D; De Maria, R; Risi, E; Ciliberto, G; Sperduti, I; Villa, A; Barba, M; Di Leo, A; Vici, P.
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
2020 Omarini, Claudia; Bettelli, Stefania Raffaella; Manfredini, Samantha; Barbolini, Monica; Isca, Chrystel; Cortesi, Giulia; Maiorana, Antonino; Tazzioli, Giovanni; Dominici, Massimo; Piacentini, Federico
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!
2020 Omarini, C.; Maur, M.; Luppi, G.; Narni, F.; Luppi, M.; Dominici, M.; Longo, G.; Piacentini, F.
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE
2020 Omarini, Claudia
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens
2021 Viansone, Alessandro; Omarini, Claudia; Boggiani, Daniela; Sikokis, Angelica; Uliana, Vera; Pellegrino, Benedetta; Piacentini, Federico; Michiara, Maria; Musolino, Antonino
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era
2021 Toss, A; Isca, C; Venturelli, M; Nasso, C; Ficarra, G; Bellelli, V; Armocida, C; Barbieri, E; Cortesi, L; Moscetti, L; Piacentini, F; Omarini, C; Andreotti, A; Gambini, A; Battista, R; Dominici, M; Tazzioli, G
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe
2021 Moscetti, ; Sperduti, I.; Frassoldati, A.; Musolino, A.; Nasso, C.; Toss, A.; Omarini, C.; Dominici, M.; Piacentini, F.
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer
2021 Barbolini, M.; Omarini, C.; Moscetti, L.; Canino, F.; Trudu, L.; Tornincasa, A.; Caggia, F.; Bettelli, S.; Manfredini, S.; Isca, C.; Molinaro, A.; Dominici, M.; Piacentini, F.
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis
2021 D'Onofrio, R.; Piacentini, F.; Barbolini, M.; Isca, C.; Nasso, C.; Caggia, F.; Dominici, M.; Moscetti, L.; Omarini, C.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. | 1-gen-2019 | Barbolini, M; Omarini, C; Viola, L; Isca, C; Marchi, I; Caggia, F; Barbieri, E; Toss, A; Cortesi, L; Dominici, M; Piacentini, F. | |
| Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). | 1-gen-2019 | Omarini, Claudia; Piacentini, Federico; Frassoldati, Antonio; Musolino, Antonino; Dominici, Massimo; Moscetti on behalf of GOIRC, Luca | |
| Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. | 1-gen-2019 | Omarini, C; Palumbo, P; Pecchi, A; Draisci, S; Balduzzi, S; Nasso, C; Barbolini, M; Isca, C; Bocconi, A; Moscetti, L; Galetti, S; Tazzioli, G; Torricelli, P; Cascinu, S; Piacentini, F. | |
| Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. | 1-gen-2019 | Omarini, Claudia; Piacentini, Federico; Sperduti, Isabella; Barbolini, Monica; Isca, Chrystel; Nasso, Cecilia; Toss, Angela; D'Onofrio, Raffaella; Cortesi, Laura; Barbieri, Elena; Cascinu, Stefano; Moscetti, Luca | |
| The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer | 1-gen-2019 | Pignata, S.; Scambia, G.; Lorusso, D.; De Giorgi, U.; Nicoletto, M. O.; Lauria, R.; Mosconi, A. M.; Sacco, C.; Omarini, C.; Tagliaferri, P.; Ferrandina, G.; Cinieri, S.; Savarese, A.; Valabrega, G.; Pisano, C.; Salutari, V.; Raspagliesi, F.; Kopf, B.; Cecere, S. C.; Amadio, G.; Maltese, G.; Di Napoli, M.; Greggi, S.; Signoriello, S.; Daniele, G.; Sacco, A.; Losito, S.; Normanno, N.; Perrone, F.; Gallo, C.; Piccirillo, M. C. | |
| Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. | 1-gen-2020 | Barbolini, Monica; Omarini, Claudia; Toss, Angela; Cortesi, Giulia; Fiorani, Claudia; Piombino, Claudia; Dominici, Massimo; Piacentini, Federico | |
| Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer | 1-gen-2020 | Isca, Chrystel; Omarini, Claudia; Cortesi, Giulia; Moscetti, Luca; Barbolini, Monica; Dominici, Massimo; Piacentini, Federico | |
| Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials | 1-gen-2020 | Omarini, C.; Piacentini, F.; Sperduti, I.; Barbolini, M.; Isca, C.; Toss, A.; Cortesi, L.; Barbieri, E.; Dominici, M.; Moscetti, L. | |
| PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis | 1-gen-2020 | D'Onofrio, R.; Omarini, C.; Barbolini, M.; Nasso, C.; Isca, C.; Dominici, M.; Piacentini, F. | |
| Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. | 1-gen-2020 | Nasso, C.; Barbolini, M.; Isca, C.; D'Onofrio, R.; Cortesi, G.; Dominici, M.; Piacentini, F.; Omarini, C. | |
| Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. | 1-gen-2020 | Barbolini, M.; Omarini, C.; Bettelli, S.; Manfredini, S.; Dominici, M.; Piacentini, F. | |
| Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting | 1-gen-2020 | Pizzuti, L; Krasniqi, E; Barchiesi, G; Della Giulia, M; Izzo, F; Sanguineti, G; Marchetti, P; Mazzotta, M; Giusti, R; Botticelli, A; Gamucci, T; Natoli, C; Grassadonia, A; Tinari, N; Iezzi, L; Tomao, S; Tomao, F; Tonini, G; Santini, D; Astone, A; Michelotti, A; De Angelis, C; Mentuccia, L; Vaccaro, A; Magnolfi, E; Gelibter, A; Magri, V; Cortesi, E; D'Onofrio, L; Cassano, A; Rossi, E; Cazzaniga, M; Moscetti, L; Omarini, C; Piacentini, F; Fabbri, Ma; Scinto, Af; Corsi, D; Carbognin, L; Bria, E; La Verde, N; Samaritani, R; Garufi, C; Barni, S; Mirabelli, R; Sarmiento, R; Veltri, E; D'Auria, G; Paris, I; Giotta, F; Lorusso, V; Cardillo, F; Landucci, E; Mauri, M; Ficorella, C; Roselli, M; Adamo, V; Ricciardi, Grr; Russo, A; Berardi, R; Pistelli, M; Fiorio, E; Cannita, K; Sini, V; D'Ostilio, N; Foglietta, J; Greco, F; Zamagni, C; Garrone, O; Di Cocco, B; Baldini, E; Livi, L; Desideri, I; Meattini, I; Sarobba, G; Del Medico, P; De Tursi, M; Generali, D; De Maria, R; Risi, E; Ciliberto, G; Sperduti, I; Villa, A; Barba, M; Di Leo, A; Vici, P. | |
| Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy | 1-gen-2020 | Omarini, Claudia; Bettelli, Stefania Raffaella; Manfredini, Samantha; Barbolini, Monica; Isca, Chrystel; Cortesi, Giulia; Maiorana, Antonino; Tazzioli, Giovanni; Dominici, Massimo; Piacentini, Federico | |
| Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! | 1-gen-2020 | Omarini, C.; Maur, M.; Luppi, G.; Narni, F.; Luppi, M.; Dominici, M.; Longo, G.; Piacentini, F. | |
| PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE | 19-mar-2020 | Omarini, Claudia | |
| Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens | 1-gen-2021 | Viansone, Alessandro; Omarini, Claudia; Boggiani, Daniela; Sikokis, Angelica; Uliana, Vera; Pellegrino, Benedetta; Piacentini, Federico; Michiara, Maria; Musolino, Antonino | |
| Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era | 1-gen-2021 | Toss, A; Isca, C; Venturelli, M; Nasso, C; Ficarra, G; Bellelli, V; Armocida, C; Barbieri, E; Cortesi, L; Moscetti, L; Piacentini, F; Omarini, C; Andreotti, A; Gambini, A; Battista, R; Dominici, M; Tazzioli, G | |
| Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe | 1-gen-2021 | Moscetti, ; Sperduti, I.; Frassoldati, A.; Musolino, A.; Nasso, C.; Toss, A.; Omarini, C.; Dominici, M.; Piacentini, F. | |
| Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer | 1-gen-2021 | Barbolini, M.; Omarini, C.; Moscetti, L.; Canino, F.; Trudu, L.; Tornincasa, A.; Caggia, F.; Bettelli, S.; Manfredini, S.; Isca, C.; Molinaro, A.; Dominici, M.; Piacentini, F. | |
| Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis | 1-gen-2021 | D'Onofrio, R.; Piacentini, F.; Barbolini, M.; Isca, C.; Nasso, C.; Caggia, F.; Dominici, M.; Moscetti, L.; Omarini, C. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile